# A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Source: https://onco.cc/trials/nct05562830/  
OnCo record `nct05562830` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Zilovertamab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) is a phase 1/2 interventional study registered as NCT05562830 by Merck Sharp & Dohme LLC, with 48 participants planned, started 2022-11-16 and due to reach its primary completion in 2029-02-26. Interventions recorded: Zilovertamab vedotin, Pembrolizumab and MK-3120.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05562830
- Phase: 1/2
- Setting: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT05562830: https://clinicaltrials.gov/study/NCT05562830

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Zilovertamab vedotin](https://onco.cc/drugs/zilovertamab-vedotin/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct05562830.json